Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.

Abstract

OBJECTIVES This study evaluated the cost effectiveness of adalimumab vs conventional therapy in patients with active ankylosing spondylitis (AS). METHODS The analysis was based on pooled data from two Phase III studies of adalimumab in active AS. Patients with an inadequate response to >/=1 NSAID received adalimumab 40 mg every other week (n = 246) or… (More)

Topics

Statistics

02040201520162017
Citations per Year

Citation Velocity: 7

Averaging 7 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Botteman2007CostEO, title={Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.}, author={Marc F. Botteman and Joanne Hay and Ming-jing Luo and Alistair S Curry and R L M Wong and Ben A. van Hout}, journal={Rheumatology}, year={2007}, volume={46 8}, pages={1320-8} }